Pharmaceutical company focused on developing psilocybin based drugs for treatment of diseases with unmet medical needs Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) has appointed Chris Ntoumenopoulosto its board of directors as an independent director.
Ntoumenopoulos is well vast with knowledge and experience when it comes to financial markets especially in raising funds and corporate strategy. Currently, Ntoumenopoulos serves as the managing director at 21 Corporate- a corporate advisory company which provides funding and corporate support for innovative companies and technologies.
“Chris is a seasoned, mission-driven advisor who supports organizations to excel beyond development and commercialization challenges. He brings both financial and biotech experience as well as a global perspective to the Tryp team. His appointment is a milestone in Tryp’s growth strategy and mission to fulfill the vast demand for innovative health solutions for underserved indications,” said the CSO and interim CEO of Tryp, Jim Gilligan.
In addition, Ntoumenopoulos is also a strategic investment adviser at Freeman Road- an investment firm focusing on health and early stages MedTech companies.
“Millions of individuals suffering from various forms of mental illness are in dire need of efficacious treatment alternatives, and Tryp is forging new ground with its tactical clinical approach. I look forward to collaborating with the team to further develop our novel drug pipeline and bring to market critical solutions to patients in need,” said Ntoumenopoulos.